INCEPT-Thromboprophylaxis

The INCEPT-Thromboprophylaxis domain has been approved, but is not yet recruiting.

Venous thromboembolism, comprising deep vein thrombosis and pulmonary embolism, is a common and potentially serious complication in intensive care unit (ICU) patients. Despite thromboprophylaxis, ICU patients are at risk of venous thromboembolism. However, ICU patients may also bleed. INCEPT-Thromboprophylaxis is an investigator-initiated, open-label domain with an integrated feasibility phase on INCEPT. The domain will assess the effects of fixed low, fixed intermediate, and weight-adjusted LMHW doses for thromboprophylaxis on the number of days alive out of hospital at 30 days and other patient-important outcomes in acutely admitted, adult ICU patients.

The INCEPT-Thromboprophylaxis domain is funded by the Novo Nordisk Foundation.

The approved domain-specific appendix and a list of key persons and domain management committee members for INCEPT-Thromboprophylaxis are available under Documents.